Amicus Therapeutics Stock Net Income
| FOLD Stock | USD 14.29 0.02 0.14% |
As of the 27th of January, Amicus Therapeutics shows the Coefficient Of Variation of 457.48, risk adjusted performance of 0.1685, and Mean Deviation of 1.59. Amicus Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Amicus Therapeutics treynor ratio, and the relationship between the variance and potential upside to decide if Amicus Therapeutics is priced correctly, providing market reflects its regular price of 14.29 per share. Given that Amicus Therapeutics has treynor ratio of 1.33, we suggest you to validate Amicus Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.
Amicus Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 7.776 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -50.5 M | -53 M | |
| Net Loss | -50.5 M | -53 M | |
| Net Loss | -212.9 M | -223.6 M | |
| Net Loss | (0.18) | (0.17) | |
| Net Income Per E B T | 1.76 | 1.84 |
Amicus | Net Income | Build AI portfolio with Amicus Stock |
Latest Amicus Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Amicus Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Amicus Therapeutics financial statement analysis. It represents the amount of money remaining after all of Amicus Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Amicus Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amicus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (56.11 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Amicus Net Income Regression Statistics
| Arithmetic Mean | (154,420,857) | |
| Coefficient Of Variation | (76.12) | |
| Mean Deviation | 102,630,706 | |
| Median | (132,118,000) | |
| Standard Deviation | 117,551,498 | |
| Sample Variance | 13818.4T | |
| Range | 349.6M | |
| R-Value | (0.23) | |
| Mean Square Error | 13971.7T | |
| R-Squared | 0.05 | |
| Significance | 0.38 | |
| Slope | (5,313,437) | |
| Total Sum of Squares | 221093.7T |
Amicus Net Income History
Other Fundumenentals of Amicus Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Amicus Therapeutics Net Income component correlations
Amicus Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Amicus Therapeutics is extremely important. It helps to project a fair market value of Amicus Stock properly, considering its historical fundamentals such as Net Income. Since Amicus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Amicus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Amicus Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.04) | Revenue Per Share | Quarterly Revenue Growth 0.195 | Return On Assets | Return On Equity |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Amicus Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Amicus Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Amicus Therapeutics.
| 10/29/2025 |
| 01/27/2026 |
If you would invest 0.00 in Amicus Therapeutics on October 29, 2025 and sell it all today you would earn a total of 0.00 from holding Amicus Therapeutics or generate 0.0% return on investment in Amicus Therapeutics over 90 days. Amicus Therapeutics is related to or competes with Ideaya Biosciences, Scholar Rock, Adaptive Biotechnologies, Arcutis Biotherapeutics, Mineralys Therapeutics, Kiniksa Pharmaceuticals, and Tarsus Pharmaceuticals. Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rar... More
Amicus Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Amicus Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Amicus Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.16 | |||
| Information Ratio | 0.198 | |||
| Maximum Drawdown | 30.77 | |||
| Value At Risk | (1.31) | |||
| Potential Upside | 3.45 |
Amicus Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Amicus Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Amicus Therapeutics' standard deviation. In reality, there are many statistical measures that can use Amicus Therapeutics historical prices to predict the future Amicus Therapeutics' volatility.| Risk Adjusted Performance | 0.1685 | |||
| Jensen Alpha | 0.8056 | |||
| Total Risk Alpha | 0.4702 | |||
| Sortino Ratio | 0.6728 | |||
| Treynor Ratio | 1.33 |
Amicus Therapeutics January 27, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1685 | |||
| Market Risk Adjusted Performance | 1.34 | |||
| Mean Deviation | 1.59 | |||
| Downside Deviation | 1.16 | |||
| Coefficient Of Variation | 457.48 | |||
| Standard Deviation | 3.94 | |||
| Variance | 15.52 | |||
| Information Ratio | 0.198 | |||
| Jensen Alpha | 0.8056 | |||
| Total Risk Alpha | 0.4702 | |||
| Sortino Ratio | 0.6728 | |||
| Treynor Ratio | 1.33 | |||
| Maximum Drawdown | 30.77 | |||
| Value At Risk | (1.31) | |||
| Potential Upside | 3.45 | |||
| Downside Variance | 1.34 | |||
| Semi Variance | (0.22) | |||
| Expected Short fall | (2.11) | |||
| Skewness | 6.57 | |||
| Kurtosis | 49.0 |
Amicus Therapeutics Backtested Returns
Amicus Therapeutics appears to be somewhat reliable, given 3 months investment horizon. Amicus Therapeutics secures Sharpe Ratio (or Efficiency) of 0.21, which signifies that the company had a 0.21 % return per unit of risk over the last 3 months. By analyzing Amicus Therapeutics' technical indicators, you can evaluate if the expected return of 0.86% is justified by implied risk. Please makes use of Amicus Therapeutics' Mean Deviation of 1.59, coefficient of variation of 457.48, and Risk Adjusted Performance of 0.1685 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Amicus Therapeutics holds a performance score of 16. The firm shows a Beta (market volatility) of 0.64, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Amicus Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Amicus Therapeutics is expected to be smaller as well. Please check Amicus Therapeutics' jensen alpha, potential upside, accumulation distribution, as well as the relationship between the treynor ratio and expected short fall , to make a quick decision on whether Amicus Therapeutics' price patterns will revert.
Auto-correlation | 0.58 |
Modest predictability
Amicus Therapeutics has modest predictability. Overlapping area represents the amount of predictability between Amicus Therapeutics time series from 29th of October 2025 to 13th of December 2025 and 13th of December 2025 to 27th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Amicus Therapeutics price movement. The serial correlation of 0.58 indicates that roughly 58.0% of current Amicus Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.58 | |
| Spearman Rank Test | 0.8 | |
| Residual Average | 0.0 | |
| Price Variance | 1.38 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Amicus Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Amicus Therapeutics reported net income of (56.11 Million). This is 116.44% lower than that of the Biotechnology sector and 180.1% lower than that of the Health Care industry. The net income for all United States stocks is 109.83% higher than that of the company.
Amicus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amicus Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Amicus Therapeutics could also be used in its relative valuation, which is a method of valuing Amicus Therapeutics by comparing valuation metrics of similar companies.Amicus Therapeutics is currently under evaluation in net income category among its peers.
Amicus Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Amicus Therapeutics from analyzing Amicus Therapeutics' financial statements. These drivers represent accounts that assess Amicus Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Amicus Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 3.1B | 3.5B | 4.2B | 2.9B | 2.6B | 2.7B | |
| Enterprise Value | 3.3B | 3.8B | 4.4B | 3.1B | 2.8B | 2.9B |
Amicus Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Amicus Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Amicus Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Amicus Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Amicus Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Amicus Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Amicus Therapeutics' value.| Shares | Palo Alto Investors, Llc | 2025-06-30 | 5.6 M | Bank Of America Corp | 2025-03-31 | 5.6 M | Jpmorgan Chase & Co | 2025-03-31 | 4.9 M | Goldman Sachs Group Inc | 2025-06-30 | 4.3 M | Vestal Point Capital Lp | 2025-03-31 | 4.3 M | Pictet Asset Manangement Sa | 2025-06-30 | 3.9 M | Massachusetts Financial Services Company | 2025-06-30 | 3.7 M | Assenagon Asset Management Sa | 2025-06-30 | 3.5 M | Nuveen, Llc | 2025-03-31 | 3.5 M | Vanguard Group Inc | 2025-06-30 | 29.4 M | Wellington Management Company Llp | 2025-06-30 | 29.1 M |
Amicus Fundamentals
| Return On Equity | -0.0687 | ||||
| Return On Asset | 0.0261 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 4.66 B | ||||
| Shares Outstanding | 313.7 M | ||||
| Shares Owned By Insiders | 0.57 % | ||||
| Shares Owned By Institutions | 99.43 % | ||||
| Number Of Shares Shorted | 19.06 M | ||||
| Price To Earning | (9.18) X | ||||
| Price To Book | 19.43 X | ||||
| Price To Sales | 7.49 X | ||||
| Revenue | 528.29 M | ||||
| Gross Profit | 537.49 M | ||||
| EBITDA | 29.39 M | ||||
| Net Income | (56.11 M) | ||||
| Cash And Equivalents | 386.84 M | ||||
| Cash Per Share | 1.38 X | ||||
| Total Debt | 443.64 M | ||||
| Debt To Equity | 2.60 % | ||||
| Current Ratio | 3.02 X | ||||
| Book Value Per Share | 0.75 X | ||||
| Cash Flow From Operations | (33.89 M) | ||||
| Short Ratio | 1.18 X | ||||
| Earnings Per Share | (0.04) X | ||||
| Price To Earnings To Growth | (0.18) X | ||||
| Target Price | 14.5 | ||||
| Number Of Employees | 499 | ||||
| Beta | 0.42 | ||||
| Market Capitalization | 4.48 B | ||||
| Total Asset | 785.03 M | ||||
| Retained Earnings | (2.74 B) | ||||
| Working Capital | 356.03 M | ||||
| Current Asset | 216.6 M | ||||
| Current Liabilities | 73.62 M | ||||
| Net Asset | 785.03 M |
About Amicus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Amicus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amicus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amicus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| HITI | High Tide | |
| HITI | High Tide | |
| BAC | Bank of America |
Check out Amicus Therapeutics Piotroski F Score and Amicus Therapeutics Altman Z Score analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.04) | Revenue Per Share | Quarterly Revenue Growth 0.195 | Return On Assets | Return On Equity |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.